Vaccines for babies
Pro Research Analysisby 
Searched over 200M research papers
Vaccines for Babies: Efficacy, Safety, and Immunogenicity
Introduction to Infant Vaccination
Vaccination in infants is a critical public health strategy aimed at reducing morbidity and mortality from infectious diseases. This article synthesizes recent research on various vaccines administered to infants, focusing on their efficacy, safety, and immunogenicity.
Maternal Vaccination and Infant Protection
RSV Vaccine During Pregnancy
A study on the bivalent RSV prefusion F protein-based (RSVpreF) vaccine administered to pregnant women demonstrated significant efficacy in preventing severe RSV-associated lower respiratory tract illness in infants. The vaccine showed an efficacy of 81.8% within 90 days and 69.4% within 180 days after birth, with no significant safety concerns for both mothers and infants .
Tdap Vaccine During Pregnancy
Research on the Tdap vaccine (tetanus-diphtheria-acellular pertussis) administered during pregnancy indicated that it provides newborns with higher levels of antibodies against pertussis. Infants of vaccinated mothers had significantly higher antibody levels at birth and during the first few months of life, although these levels were lower after the primary vaccine series .
Group B Streptococcus Vaccine
A trivalent Group B Streptococcus (GBS) vaccine administered to pregnant women was found to be well-tolerated and effective in inducing capsular-specific antibody responses. This maternal vaccination led to higher GBS serotype-specific antibody concentrations in infants, suggesting potential protection against neonatal GBS invasive disease .
Vaccination in Preterm Infants
Penta- and Hexavalent Vaccines
Studies on penta- and hexavalent vaccines (which protect against multiple diseases) in preterm infants showed that these vaccines are generally as immunogenic and safe as in full-term infants. However, preterm infants exhibited a higher incidence of cardiorespiratory adverse events such as apnea and bradycardia, necessitating close monitoring post-vaccination Knuf2023Chiappini2019.
DTaP-IPV-Hib-HepB Vaccine
The hexavalent DTaP-IPV-Hib-HepB vaccine (Vaxelis™) was evaluated in premature infants and found to have a safety and immunogenicity profile comparable to that in full-term infants. The vaccine elicited satisfactory immune responses, supporting its use in healthy premature infants .
Immunogenicity and Safety of Specific Vaccines
Pneumococcal Conjugate Vaccine (PCV13)
A study comparing different dosing schedules of the PCV13 vaccine in UK infants found that a reduced priming schedule (1+1) was as effective as the standard schedule (2+1) for most serotypes. This suggests that a single priming dose followed by a booster could maintain population control of pneumococcal disease in countries with established herd immunity .
Tetravalent Pneumococcal Vaccines
Tetravalent pneumococcal vaccines containing polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid were well-tolerated and induced significant serotype-specific anticapsular antibodies in young infants. These vaccines also demonstrated immunologic memory, indicating their potential for long-term protection .
Conclusion
The research highlights the effectiveness and safety of various vaccines administered to infants, including those given to pregnant women to protect their newborns. Vaccines such as RSVpreF, Tdap, and GBS show promise in reducing infant morbidity from specific infections. Additionally, penta- and hexavalent vaccines, as well as pneumococcal conjugate vaccines, are effective in both full-term and preterm infants, although close monitoring is recommended for preterm infants due to higher risks of adverse events. These findings underscore the importance of continued research and vaccination to protect infants from preventable diseases.
Sources and full results
Most relevant research papers on this topic